Enhancing cancer vaccine efficacy via electrostatic engineering of an FcγR-targeted protein - Takeaways - MDSpire

Enhancing cancer vaccine efficacy via electrostatic engineering of an FcγR-targeted protein

  • By

  • Chiao-Chieh Wu

  • Chia-Ling Chen

  • Chen-Yi Chiang

  • Ling-Ling Tu

  • Shih-Jen Liu

  • Chih-Hsiang Leng

  • Hisn-Wei Chen

  • May 22, 2026

  • 0 min

Share

  • 1

    The study developed rF9R, a modified FLIPr protein, to enhance cancer vaccine delivery and immune response through electrostatic interactions.

  • 2

    rF9R successfully formed stable complexes with peptides and antigens, significantly improving antigen delivery and immune activation.

  • 3

    In vivo tests showed that the rF9R/rE7m complex elicited strong CD8+ T-cell responses and led to significant tumor regression.

  • 4

    The rF9R platform serves as an efficient carrier and immunostimulatory component, simplifying peptide and subunit vaccine delivery.

  • 5

    This research highlights rF9R's potential to address challenges in cancer vaccine development and improve immunotherapy outcomes.

Original Source(s)

Enhancing cancer vaccine efficacy via electrostatic engineering of an FcγR-targeted protein

  • by Chiao-Chieh Wu, Chia-Ling Chen, Chen-Yi Chiang, Ling-Ling Tu, Shih-Jen Liu, Chih-Hsiang Leng, Hisn-Wei Chen

  • May 22, 2026

Related Content

Glioblastoma, IDH-wildtype, with a novel MEF2D-NTRK1 gene fusion: a case report

MRI perfusion in evaluating ovarian masses: diagnostic performance of wash out rate

High-grade astrocytoma with piloid features: a case report of comprehensive management